Leukocytapheresis Therapy Improved Cholestasis in a Patient Suffering from Primary Sclerosing Cholangitis with Ulcerative Colitis

por Itou, Minoru, Mitsuyama, Keiichi, Kawaguchi, Takumi, Okabe, Yoshinobu, Suga, Hideya, Masuda, Junya, Yamasaki, Hiroshi, Kuwaki, Kotaro, Taniguchi, Eitaro, Harada, Masaru, Tsuruta, Osamu, Sata, Michio
Publicado 2009

A phase II study of gemcitabine plus nab-paclitaxel as first-line therapy for locally advanced pancreatic cancer

por Fukahori, Masaru, Miwa, Keisuke, Murotani, Kenta, Naito, Yoshiki, Ushijima, Tomoyuki, Sakaue, Takahiko, Tanaka, Toshimitsu, Nagasu, Sachiko, Suga, Hideya, Kakuma, Tatsuyuki, Okabe, Yoshinobu, Torimura, Takuji
Publicado 2021

Efficacy of Lenvatinib Combined with Transcatheter Intra-Arterial Therapies for Patients with Advanced-Stage of Hepatocellular Carcinoma: A Propensity Score Matching

por Shimose, Shigeo, Iwamoto, Hideki, Niizeki, Takashi, Tanaka, Masatoshi, Shirono, Tomotake, Moriyama, Etsuko, Noda, Yu, Nakano, Masahito, Suga, Hideya, Kuromatsu, Ryoko, Torimura, Takuji, Koga, Hironori, Kawaguchi, Takumi
Publicado 2023

Controlling Nutritional Status (CONUT) Score is Associated with Overall Survival in Patients with Unresectable Hepatocellular Carcinoma Treated with Lenvatinib: A Multicenter Cohor...

por Shimose, Shigeo, Kawaguchi, Takumi, Iwamoto, Hideki, Tanaka, Masatoshi, Miyazaki, Ken, Ono, Miki, Niizeki, Takashi, Shirono, Tomotake, Okamura, Shusuke, Nakano, Masahito, Suga, Hideya, Yamaguchi, Taizo, Yokokura, Yoshinori, Noguchi, Kazunori, Koga, Hironori, Torimura, Takuji
Publicado 2020

Lenvatinib prolongs the progression-free survival time of patients with intermediate-stage hepatocellular carcinoma refractory to transarterial chemoembolization: A multicenter coh...

por Shimose, Shigeo, Kawaguchi, Takumi, Tanaka, Masatoshi, Iwamoto, Hideki, Miyazaki, Ken, Moriyama, Etsuko, Suzuki, Hiroyuki, Niizeki, Takashi, Shirono, Tomotake, Nakano, Masahito, Suga, Hideya, Yamaguchi, Taizo, Yokokura, Yoshinori, Noguchi, Kazunori, Koga, Hironori, Torimura, Takuji
Publicado 2020

Clinical Significance of Adverse Events for Patients with Unresectable Hepatocellular Carcinoma Treated with Lenvatinib: A Multicenter Retrospective Study

por Shimose, Shigeo, Iwamoto, Hideki, Niizeki, Takashi, Shirono, Tomotake, Noda, Yu, Kamachi, Naoki, Okamura, Shusuke, Nakano, Masahito, Suga, Hideya, Kuromatsu, Ryoko, Yamaguchi, Taizo, Kawaguchi, Takumi, Tanaka, Masatoshi, Noguchi, Kazunori, Koga, Hironori, Torimura, Takuji
Publicado 2020

Alternating Lenvatinib and Trans-Arterial Therapy Prolongs Overall Survival in Patients with Inter-Mediate Stage HepatoCellular Carcinoma: A Propensity Score Matching Study

por Shimose, Shigeo, Iwamoto, Hideki, Tanaka, Masatoshi, Niizeki, Takashi, Shirono, Tomotake, Noda, Yu, Kamachi, Naoki, Okamura, Shusuke, Nakano, Masahito, Suga, Hideya, Yamaguchi, Taizo, Kawaguchi, Takumi, Kuromatsu, Ryoko, Noguchi, Kazunori, Koga, Hironori, Torimura, Takuji
Publicado 2021

Deterioration of liver function and aging disturb sequential systemic therapy for unresectable hepatocellular carcinoma

por Shimose, Shigeo, Hiraoka, Atsushi, Tanaka, Masatoshi, Iwamoto, Hideki, Tanaka, Takaaki, Noguchi, Kazunori, Aino, Hajime, Yamaguchi, Taizo, Itano, Satoshi, Suga, Hideya, Niizeki, Takashi, Moriyama, Etsuko, Shirono, Tomotake, Noda, Yu, Kamachi, Naoki, Okamura, Shusuke, Nakano, Masahito, Kawaguchi, Takumi, Kuromatsu, Ryoko, Koga, Hironori, Torimura, Takuji
Publicado 2022

First‐line sorafenib sequential therapy and liver disease etiology for unresectable hepatocellular carcinoma using inverse probability weighting: A multicenter retrospective study...

por Shimose, Shigeo, Hiraoka, Atsushi, Nakano, Masahito, Iwamoto, Hideki, Tanaka, Masatoshi, Tanaka, Takaaki, Noguchi, Kazunori, Aino, Hajime, Ogata, Kei, Kajiwara, Masahiko, Itano, Satoshi, Yokokura, Yoshinori, Yamaguchi, Taizo, Kawano, Hiroshi, Matsukuma, Norito, Suga, Hideya, Niizeki, Takashi, Shirono, Tomotake, Noda, Yu, Kamachi, Naoki, Okamura, Shusuke, Kawaguchi, Takumi, Koga, Hironori, Torimura, Takuji
Publicado 2021